MX2019010643A - Formas y composiciones de un inhibidor de proteina cinasa 2 activada por la proteina cinasa activada por mitogeno (mk2). - Google Patents

Formas y composiciones de un inhibidor de proteina cinasa 2 activada por la proteina cinasa activada por mitogeno (mk2).

Info

Publication number
MX2019010643A
MX2019010643A MX2019010643A MX2019010643A MX2019010643A MX 2019010643 A MX2019010643 A MX 2019010643A MX 2019010643 A MX2019010643 A MX 2019010643A MX 2019010643 A MX2019010643 A MX 2019010643A MX 2019010643 A MX2019010643 A MX 2019010643A
Authority
MX
Mexico
Prior art keywords
inhibitor
compositions
forms
methods
same
Prior art date
Application number
MX2019010643A
Other languages
English (en)
Other versions
MX393600B (es
Inventor
Li Ying
Xu Jean
L Ruchelman Alexander
Jain Uday
Zou Daozhong
Huang Lianfeng
MALONA John
Pabba Chittari
Han Jianxin
MOLTER Kevin
Original Assignee
Celgene Car Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Celgene Car Llc filed Critical Celgene Car Llc
Publication of MX2019010643A publication Critical patent/MX2019010643A/es
Publication of MX393600B publication Critical patent/MX393600B/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D495/14—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/005—Enzyme inhibitors

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Cosmetics (AREA)

Abstract

La presente invención se refiere a formas sólidas de un inhibidor de MK2, composiciones de los mismos, y métodos para usar los mismos.
MX2019010643A 2017-03-16 2018-03-15 Formas y composiciones de un inhibidor de proteina cinasa 2 activada por la proteina cinasa activada por mitogeno (mk2). MX393600B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201762472015P 2017-03-16 2017-03-16
PCT/US2018/022543 WO2018170199A1 (en) 2017-03-16 2018-03-15 Forms and compositions of a mk2 inhibitor

Publications (2)

Publication Number Publication Date
MX2019010643A true MX2019010643A (es) 2019-10-17
MX393600B MX393600B (es) 2025-03-24

Family

ID=63522534

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2019010643A MX393600B (es) 2017-03-16 2018-03-15 Formas y composiciones de un inhibidor de proteina cinasa 2 activada por la proteina cinasa activada por mitogeno (mk2).

Country Status (8)

Country Link
US (2) US10882867B2 (es)
EP (1) EP3595658A4 (es)
JP (2) JP2020514360A (es)
CN (1) CN110678178B (es)
AU (1) AU2018236286B2 (es)
CA (1) CA3054823A1 (es)
MX (1) MX393600B (es)
WO (1) WO2018170199A1 (es)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EA037299B1 (ru) 2014-09-17 2021-03-05 Селджен Кар Ллс Ингибиторы mk2 и их применения
WO2018170201A1 (en) 2017-03-16 2018-09-20 Celgene Car Llc Deuterated analogs of mk2 inhibitors and uses thereof
US11098057B2 (en) 2017-03-16 2021-08-24 Celgene Car Llc 9,10,11,12-tetrahydro-8H-[1,4]diazepino[5′,6′:4,5]thieno[3,2-F]quinolin-8-one compounds and uses thereof
MX387359B (es) 2017-03-16 2025-03-18 Bristol Myers Squibb Co Inhibidores de cinasa activada por mitógeno 2 (mk2), síntesis de los mismos, e intermediarios de los mismos.
CN110678178B (zh) 2017-03-16 2023-10-03 百时美施贵宝公司 Mk2抑制剂的形式和组合物
US11124525B2 (en) 2017-03-16 2021-09-21 Celgene Car Llc Heteroaryl compounds useful as MK2 inhibitors
KR20220041042A (ko) * 2019-05-17 2022-03-31 셀젠 카르 엘엘씨 Mk2-매개 장애를 치료하는 방법
AR124726A1 (es) 2021-02-01 2023-04-26 Celgene Corp Inhibidores de nk2, su síntesis y sus intermedios
KR20240134978A (ko) 2022-01-14 2024-09-10 상하이 한서 바이오메디컬 컴퍼니 리미티드 피리딘 함유 폴리시클릭 유도체, 이의 제조 방법 및 용도

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2251292A1 (en) * 1996-04-12 1997-10-23 Bristol-Myers Squibb Company N-formyl hydroxylamine containing compounds useful as ace inhibitors and/or nep inhibitors
WO2004058176A2 (en) 2002-12-20 2004-07-15 Pharmacia Corporation Acyclic pyrazole compounds
WO2005105814A1 (en) 2004-04-28 2005-11-10 Incyte Corporation Tetracyclic inhibitors of janus kinases
US7790712B2 (en) * 2005-03-17 2010-09-07 Boehringer Ingelheim Pharmaceutical, Inc. Substituted [1,4]diazepino[1,2-A]indoles and azepino[1,2-A]indoles as anti-cytokine inhibitors
CN101360750A (zh) * 2005-11-23 2009-02-04 英特芒尼公司 应激活化蛋白激酶系统的调节方法
EP2178874A1 (en) 2007-07-16 2010-04-28 Novartis Ag Heterocyclic compounds useful as mk2 inhibitors
CN102753179A (zh) * 2009-11-17 2012-10-24 密执安大学评议会 具有治疗性能的1,4-苯并二氮杂*-2,5-二酮和相关化合物
WO2011153553A2 (en) 2010-06-04 2011-12-08 The Regents Of The University Of California Methods and compositions for kinase inhibition
CN102464639A (zh) * 2010-11-16 2012-05-23 北京京卫信康医药科技发展有限公司 麦考酚酸钠的新晶型及其制备方法
KR101649610B1 (ko) * 2011-04-21 2016-08-19 오리제니스 게엠베하 키나아제 억제제로서의 헤테로사이클릭 화합물
EP2872144A4 (en) 2012-07-11 2015-12-02 Nimbus Iris Inc IRAQ INHIBITOR AND USES THEREOF
CA2908098A1 (en) 2013-03-15 2014-09-25 Celgene Avilomics Research, Inc. Mk2 inhibitors and uses thereof
US9695193B2 (en) * 2013-06-26 2017-07-04 The Trustees Of Columbia University In The City Of New York Inhibitors of Plasmodium falciparum equilibrative nucleoside transporter type I as anti-parasitic compounds
US10512651B2 (en) 2014-08-25 2019-12-24 Stc.Unm Inhibition of MK2 in the treatment of cancer
EA037299B1 (ru) 2014-09-17 2021-03-05 Селджен Кар Ллс Ингибиторы mk2 и их применения
BR112017014737A2 (pt) 2015-01-08 2018-01-16 Moerae Matrix Inc formulação de peptídeos inibidores de mk2
MX387359B (es) 2017-03-16 2025-03-18 Bristol Myers Squibb Co Inhibidores de cinasa activada por mitógeno 2 (mk2), síntesis de los mismos, e intermediarios de los mismos.
CN110678178B (zh) 2017-03-16 2023-10-03 百时美施贵宝公司 Mk2抑制剂的形式和组合物
US11098057B2 (en) 2017-03-16 2021-08-24 Celgene Car Llc 9,10,11,12-tetrahydro-8H-[1,4]diazepino[5′,6′:4,5]thieno[3,2-F]quinolin-8-one compounds and uses thereof
WO2018170201A1 (en) 2017-03-16 2018-09-20 Celgene Car Llc Deuterated analogs of mk2 inhibitors and uses thereof
US11124525B2 (en) 2017-03-16 2021-09-21 Celgene Car Llc Heteroaryl compounds useful as MK2 inhibitors
KR20220041042A (ko) 2019-05-17 2022-03-31 셀젠 카르 엘엘씨 Mk2-매개 장애를 치료하는 방법
JP2023536427A (ja) 2020-07-24 2023-08-25 ブリストル－マイヤーズ スクイブ カンパニー 急性呼吸器障害の治療方法
AR124726A1 (es) 2021-02-01 2023-04-26 Celgene Corp Inhibidores de nk2, su síntesis y sus intermedios

Also Published As

Publication number Publication date
JP2023017840A (ja) 2023-02-07
AU2018236286A1 (en) 2019-09-19
CA3054823A1 (en) 2018-09-20
CN110678178B (zh) 2023-10-03
EP3595658A1 (en) 2020-01-22
MX393600B (es) 2025-03-24
US11629153B2 (en) 2023-04-18
CN110678178A (zh) 2020-01-10
JP2020514360A (ja) 2020-05-21
WO2018170199A1 (en) 2018-09-20
US20200148701A1 (en) 2020-05-14
AU2018236286B2 (en) 2022-02-17
EP3595658A4 (en) 2020-11-25
US20210198276A1 (en) 2021-07-01
US10882867B2 (en) 2021-01-05

Similar Documents

Publication Publication Date Title
MX2019010643A (es) Formas y composiciones de un inhibidor de proteina cinasa 2 activada por la proteina cinasa activada por mitogeno (mk2).
MX2022007576A (es) Degradadores de cinasas asociadas al receptor de interleucina-1 (irak) y usos de los mismos.
MX2021006154A (es) Degradadores de cinasas asociadas al receptor de interleucina 1 (irak) y usos de los mismos.
CY1124215T1 (el) Μκ2 αναστολεις και χρησεις αυτων
CL2018001790A1 (es) Procesos para preparar un inhibidor de jak1 y nuevas formas de este (divisional solicitud 201602748)
MX2020009461A (es) Anticuerpos anti-proteína que contiene dominio de inmunologlubina rfig elacionado con el receptor de poliovirus (pvrig) y métodos de uso.
MX388018B (es) Anticuerpos anti-pd1 y métodos de uso.
MX2020003857A (es) Anticuerpos anti-tau y uso de los mismos.
CU20190006A7 (es) Composiciones para inhibir masp-3
EA201992177A1 (ru) Композиции на основе нирапариба
BR112019012342A2 (pt) anticorpos il-11
MX2022000053A (es) Moduladores de interaccion de sestrina-gator2 y sus usos.
BR112019012343A2 (pt) anticorpos il-11ra
CY1124338T1 (el) Αναστολεις 3-φωσφογλυκερικης αφυδρογονασης και χρησεις αυτων
CR20160419A (es) Nuevos compuestos biciclicos
MX2017014299A (es) Inhibidores de histona deacetilasa y composiciones y metodos para el uso de los mismos.
MX373818B (es) Composiciones de apilimod y métodos para usar las mismas.
MX2020013630A (es) Analogos de rapamicina y usos de los mismos.
MX2020001885A (es) Formulaciones de daptomicina.
UY36500A (es) Composiciones del inhibidor de la nitrificación y métodos de preparación de las mismas
EP3710546A4 (en) NOVEL SYNTHETIC CAUSTIC COMPOSITION
DOP2018000066A (es) Compuestos útiles para inhibir ror-gamma-t
MX2017011218A (es) Composiciones edulcorantes que contienen rebaudiosidos d.
CO2017001389A2 (es) Compuestos de azetidiniloxifenilpirrolidina
DOP2020000104A (es) Métodos de uso y composiciones que contienen dulaglutida